Carrier-based strategies for targeting protein and peptide drugs to the lungs.
about
Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.Pharmaceutical particle engineering via spray drying.Nanomedicine in pulmonary deliveryInhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Biodistribution and Efficacy of Targeted Pulmonary Delivery of a Protein Kinase C-δ Inhibitory Peptide: Impact on Indirect Lung Injury.Factors of importance for a successful delivery system for proteins.Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases.Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Preparation and characterization of curcumin-piperine dual drug loaded nanoparticlesDesign of fine particles for pulmonary drug delivery.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.Targeted gene delivery to the lung.Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors.Nanocarriers for pulmonary administration of peptides and therapeutic proteins.Mifamurtide for the treatment of nonmetastatic osteosarcomaInhaled chemotherapy in lung cancer: future concept of nanomedicine.Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system.Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-κB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells.Overcoming obstacles in microRNA delivery towards improved cancer therapy.Oxytocin and Social Relationships: From Attachment to Bond Disruption.Barriers to Liposomal Gene Delivery: from Application Site to the Target.Liposome-targeted delivery for highly potent drugs.Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma.Effect of cholesterol on the properties of spray-dried lysozyme-loaded liposomal powders.Polyketal microparticles for therapeutic delivery to the lung.Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma.Construction and evaluation in vitro and in vivo of tedizolid phosphate loaded cationic liposomes.Protective effect of magnolol-loaded polyketal microparticles on lipopolysaccharide-induced acute lung injury in rats.Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies
P2860
Q30431758-EEC6983A-6BE3-4D66-BE1E-E7E7EB0214B7Q30496354-CF1525B0-9372-4416-9C02-FEE958A96CA7Q33572981-4B61090D-A808-4D78-A868-224FC8C42E36Q33810383-7B7EDD08-7692-47B0-8D26-B6A6C891854FQ33858681-0978AB51-A7FB-4D82-8903-7D57F43AE00AQ34588395-FD91CEB0-6A04-48D5-A3F9-68DA4828742DQ36077663-90794614-D446-4690-BB36-12FEA772890EQ36316926-A1C5D1AD-B2DA-4E2F-8E35-23AF9B298E74Q36321710-E3512242-AE9C-4DFD-8B4D-66FE8613F524Q36360151-42439743-9322-4413-9A59-A60AAC803268Q36512499-F9B4D673-AD22-43E7-A9BF-7F9FBF795DEFQ36719569-5C633246-BF2E-4A25-A93D-3BCAF927D456Q36815946-ADAD756C-C52C-485E-83B3-426272A0B561Q36853886-55892222-DE98-4CCA-9CAB-D2CCBCC3361FQ37486747-C26BEAB4-3BEC-4C4F-B89F-39CCC027896FQ37644500-C89E93CD-DC31-4ABE-8F33-00594943E9FEQ37823598-497ECD49-6713-44D9-8B32-A65D0AE2BD28Q37827876-A8EC1242-9C86-433C-A98B-A05C73643E2BQ38012447-B19398A0-1519-414C-953E-336423492906Q38033610-43D651A0-531E-4E48-9C8C-CFABBFE50136Q38038897-25E9460E-2FD0-44FD-A937-A24008977A37Q38096410-6702F13B-4F76-43F3-8FB4-D544EB109C11Q38337325-1C6816F0-8A92-4E39-9E51-2818FB1C5C2CQ38382967-3A94AC00-88C3-485E-87F4-682489BF57ADQ38622644-A6CED24D-BBF1-465D-93F8-DBE787742735Q39147224-0E309828-0BE9-422F-AD66-F16D51E0B1B4Q39171223-0CCAF7AC-1F4A-4ED0-9E3F-5FCEEA6286AEQ39547201-8D2A9934-10A6-4210-9EAC-EAB922F97A29Q41948576-20FD3FB3-6AD5-4E2B-AF19-90692134E510Q42176770-9DAFF047-D5D4-4AA4-A16A-926084E045CBQ43248720-F09C4ED6-949A-4397-A4B9-A9753ED02035Q47684025-7976DE3C-3911-4C67-8A04-1D23A94D29ADQ51274597-ED36972F-E02B-48A2-AE3C-C8BEB26CA9C3Q57172145-00F1B522-428C-40E4-A371-9A0276F62F40
P2860
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@ast
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@en
type
label
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@ast
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@en
prefLabel
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@ast
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@en
P2860
P356
P1433
P1476
Carrier-based strategies for targeting protein and peptide drugs to the lungs.
@en
P2860
P2888
P304
P356
10.1208/AAPSJ070104
P407
P577
2005-03-24T00:00:00Z
P5875
P6179
1033011881